Symbiotec Pharmalab Ltd

Symbiotec Pharmalab Private Limited was incorporated as a private limited company, dated September 20, 2002, with the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, the name of the Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, was issued by the Central Processing Centre. Symbiotec is one of the few companies globally and only Indian manufacturer having continuous manufacturing for progesterone API manufacturing. The Company has its flow chemistry capability being utilized for progesterone in a new block in Pithampur facility. It is presently engaged in manufacturing and selling of Active Pharmaceuticals Ingredients (API) and Intermediates. The Company has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients. With over 30 years of industry experience, it has evolved from a lab-scale steroidal-hormone API manufacturer in year 1995 into an industrial-scale, backward-integrated platform with approvals from the United States Food and Drug Administration (USFDA), European Union Good Manufacturing Practices (EU-GMP), Ministry of Food and Drug Safety, Korea and other global organisations. The Company started production of APIs at the Rau Facility in year 2004 and later commenced the same including hormone synthesis at the Pithampur Facility in 2010. In 2012, it commissioned a 5 KL biotech plant at Pithampur and a 35 kilolitres (KL) fermentation project at the Pithampur Facility. The Company had two operational industrial-scale API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tons and fermentation capacity of 300 kilolitres. It has commissioned two additional manufacturing facilities, leading to an aggregate maximum chemical synthesis capacity of 584.67 MT, maximum fermentation capacity of 700 KL, and complex injectables capacity of 20 million vials per annum. The Company later expanded a sterile plant at the Rau Facility in 2022-23. It has commissioned a complex injectables facility at the Mhow and further installed a 400 KL at the Ujjain Plant in FY 2025. Company has filed a Draft Red Herring Prospectus with SEBI and is planning to raise funds through IPO aggregating to Rs 2180 crores, consisting a fresh offer of Rs 150 crore and the offer for sale of Rs 2030 crores having the face value of Rs 2 each.